JP2013501816A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013501816A5 JP2013501816A5 JP2012524910A JP2012524910A JP2013501816A5 JP 2013501816 A5 JP2013501816 A5 JP 2013501816A5 JP 2012524910 A JP2012524910 A JP 2012524910A JP 2012524910 A JP2012524910 A JP 2012524910A JP 2013501816 A5 JP2013501816 A5 JP 2013501816A5
- Authority
- JP
- Japan
- Prior art keywords
- erythropoietin
- combination
- erythropoietin receptor
- medicament according
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/583,177 US8058229B2 (en) | 2008-08-14 | 2009-08-13 | Method of increasing red blood cell levels or treating anemia in a patient |
| USPCT/US2009/004659 | 2009-08-13 | ||
| US12/583,177 | 2009-08-13 | ||
| PCT/US2009/004659 WO2010019261A1 (en) | 2008-08-14 | 2009-08-13 | Use of gdf traps to increase red blood cell levels |
| US30590110P | 2010-02-18 | 2010-02-18 | |
| US61/305,901 | 2010-02-18 | ||
| PCT/US2010/045509 WO2011020045A1 (en) | 2009-08-13 | 2010-08-13 | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236828A Division JP2016034981A (ja) | 2009-08-13 | 2015-12-03 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013501816A JP2013501816A (ja) | 2013-01-17 |
| JP2013501816A5 true JP2013501816A5 (https=) | 2013-09-19 |
| JP5909446B2 JP5909446B2 (ja) | 2016-04-26 |
Family
ID=43586530
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012524910A Active JP5909446B2 (ja) | 2009-08-13 | 2010-08-13 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2015236828A Withdrawn JP2016034981A (ja) | 2009-08-13 | 2015-12-03 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2018153528A Active JP6860533B2 (ja) | 2009-08-13 | 2018-08-17 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2020163806A Pending JP2020203953A (ja) | 2009-08-13 | 2020-09-29 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015236828A Withdrawn JP2016034981A (ja) | 2009-08-13 | 2015-12-03 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2018153528A Active JP6860533B2 (ja) | 2009-08-13 | 2018-08-17 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
| JP2020163806A Pending JP2020203953A (ja) | 2009-08-13 | 2020-09-29 | 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用 |
Country Status (13)
| Country | Link |
|---|---|
| EP (3) | EP3838919A1 (https=) |
| JP (4) | JP5909446B2 (https=) |
| KR (5) | KR102606494B1 (https=) |
| CN (7) | CN113082194B (https=) |
| AU (1) | AU2010282361B2 (https=) |
| BR (2) | BR112012003232B1 (https=) |
| CA (1) | CA2770822C (https=) |
| ES (2) | ES2844123T3 (https=) |
| IL (6) | IL287990B (https=) |
| MX (2) | MX2012001916A (https=) |
| NZ (3) | NZ712943A (https=) |
| RU (2) | RU2592670C2 (https=) |
| WO (1) | WO2011020045A1 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| ES2649983T3 (es) | 2005-11-23 | 2018-01-16 | Acceleron Pharma, Inc. | Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| MX2009008222A (es) | 2007-02-01 | 2009-10-12 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama. |
| TW201803890A (zh) | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| EA018221B1 (ru) | 2007-02-09 | 2013-06-28 | Акселерон Фарма Инк. | АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ |
| CN101861161B (zh) | 2007-09-18 | 2017-04-19 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| TW201803586A (zh) | 2008-08-14 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| KR20120049214A (ko) | 2009-06-08 | 2012-05-16 | 악셀레론 파마 인코포레이티드 | 발열성 지방세포를 증가시키는 방법 |
| KR20180026795A (ko) | 2009-06-12 | 2018-03-13 | 악셀레론 파마 인코포레이티드 | 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질 |
| EP3332796A1 (en) | 2009-11-17 | 2018-06-13 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| AU2011326586A1 (en) | 2010-11-08 | 2013-05-30 | Acceleron Pharma, Inc. | ActRIIA binding agents and uses thereof |
| KR20140084211A (ko) * | 2011-10-17 | 2014-07-04 | 악셀레론 파마 인코포레이티드 | 효과가 없는 적혈구생성 치료를 위한 방법 및 조성물 |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| CN104968801B (zh) * | 2012-10-24 | 2021-06-15 | 细胞基因公司 | 用于治疗贫血症的生物标志物 |
| HK1214504A1 (zh) * | 2012-10-24 | 2016-07-29 | 细胞基因公司 | 用於治療貧血的方法 |
| US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| JP2017509647A (ja) | 2014-03-21 | 2017-04-06 | アクセルロン ファーマ， インコーポレイテッド | アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法 |
| CN114699529A (zh) | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| US10603359B2 (en) | 2014-10-30 | 2020-03-31 | Acceleron Pharma Inc. | Methods and compositions using GDF15 polypeptides for increasing red blood cells |
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| JP2018501307A (ja) * | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| WO2016128523A1 (en) * | 2015-02-12 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| CA2983440C (en) | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| CN108350057A (zh) * | 2015-05-20 | 2018-07-31 | 细胞基因公司 | 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法 |
| WO2017079591A2 (en) * | 2015-11-04 | 2017-05-11 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| EP3380121B1 (en) | 2015-11-23 | 2023-12-20 | Acceleron Pharma Inc. | Actrii antagonist for use in treating eye disorders |
| US20170240639A1 (en) * | 2016-02-22 | 2017-08-24 | Acceleron Pharma Inc. | Actrii antagonists for use in increasing immune activity |
| DK3496739T3 (da) | 2016-07-15 | 2021-05-10 | Acceleron Pharma Inc | Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension |
| MA45811A (fr) * | 2016-07-27 | 2019-06-05 | Acceleron Pharma Inc | Méthodes et compositions de traitement de maladie. |
| CN110036025B (zh) * | 2016-10-05 | 2024-03-22 | 阿塞勒隆制药公司 | 变体ActRIIB蛋白及其用途 |
| CA3039074A1 (en) | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Compositions and method for treating kidney disease |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| NZ754161A (en) | 2016-11-10 | 2025-11-28 | Keros Therapeutics Inc | Activin receptor type iia variants and methods of use thereof |
| PL3638243T3 (pl) | 2017-06-14 | 2025-02-10 | Celgene Corporation | Sposoby leczenia mielofibrozy związanej z nowotworem mieloproliferacyjnym i niedokrwistości |
| CA3082146A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| KR20250133994A (ko) * | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| US12310982B2 (en) | 2018-12-10 | 2025-05-27 | Elena Valentinovna ARSHINTSEVA | Use of the poloxamer as a pharmacologically active substance |
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| WO2021189019A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Activin receptor type ii chimeras and methods of use thereof |
| CN111466337B (zh) * | 2020-05-19 | 2022-04-19 | 山东大学齐鲁医院 | 一种腹主动脉瘤动物模型及其构建方法 |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| CN115317589B (zh) * | 2022-09-05 | 2024-12-13 | 中国海洋大学 | 脯氨酰羟化酶抑制剂及其应用 |
| CN119198238A (zh) * | 2024-09-18 | 2024-12-27 | 广东省安家医健健康管理有限公司 | 一种地中海贫血检测系统及试剂盒 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1265208A (en) | 1915-09-07 | 1918-05-07 | Edward C Kahn | Liquid-fuel burner. |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| NZ306767A (en) | 1995-04-11 | 2000-03-27 | Univ Johns Hopkins | Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems |
| MXPA01007366A (es) | 1999-01-21 | 2002-06-04 | Metamorphix Inc | Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos. |
| ME00673B (me) * | 2000-05-15 | 2011-12-20 | Hoffmann La Roche | Nova farmaceutska smjesa |
| US7087224B2 (en) * | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| DK2298301T3 (en) * | 2001-12-06 | 2018-10-01 | Fibrogen Inc | MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease |
| DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| ATE419846T1 (de) * | 2003-02-07 | 2009-01-15 | Prometic Biosciences Inc | Fettsäuren mittlerer kettenlänge, glyceride und analoga als stimulatoren der erythropoiese |
| GB0304424D0 (en) * | 2003-02-26 | 2003-04-02 | Glaxosmithkline Biolog Sa | Novel compounds |
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| WO2006063101A2 (en) * | 2004-12-09 | 2006-06-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Vaccines for the rapid response to pandemic avian influenza |
| EP1884235A1 (en) * | 2005-04-26 | 2008-02-06 | Ajinomoto Co., Inc. | Myeloerythroid progenitor differentiation inducer |
| CA2623531C (en) * | 2005-10-07 | 2013-12-10 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Matrix metalloproteinase 11 vaccine |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| US20100003190A1 (en) * | 2006-12-08 | 2010-01-07 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN) |
| CN104524548A (zh) * | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
| TW201803890A (zh) * | 2007-02-02 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| DK2318028T3 (da) * | 2008-06-26 | 2020-05-04 | Acceleron Pharma Inc | Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer |
| TW201803586A (zh) * | 2008-08-14 | 2018-02-01 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
-
2010
- 2010-08-13 AU AU2010282361A patent/AU2010282361B2/en active Active
- 2010-08-13 ES ES16186033T patent/ES2844123T3/es active Active
- 2010-08-13 WO PCT/US2010/045509 patent/WO2011020045A1/en not_active Ceased
- 2010-08-13 KR KR1020227045338A patent/KR102606494B1/ko active Active
- 2010-08-13 EP EP20197940.8A patent/EP3838919A1/en not_active Withdrawn
- 2010-08-13 NZ NZ712943A patent/NZ712943A/en unknown
- 2010-08-13 EP EP10808838.6A patent/EP2464369B1/en active Active
- 2010-08-13 KR KR1020207030283A patent/KR20200124322A/ko not_active Ceased
- 2010-08-13 ES ES10808838T patent/ES2796121T3/es active Active
- 2010-08-13 RU RU2012109393/10A patent/RU2592670C2/ru active
- 2010-08-13 CN CN202110417494.3A patent/CN113082194B/zh active Active
- 2010-08-13 CN CN202110421547.9A patent/CN113171442B/zh active Active
- 2010-08-13 JP JP2012524910A patent/JP5909446B2/ja active Active
- 2010-08-13 BR BR112012003232-1A patent/BR112012003232B1/pt active IP Right Grant
- 2010-08-13 KR KR1020197027722A patent/KR102170682B1/ko active Active
- 2010-08-13 IL IL287990A patent/IL287990B/en unknown
- 2010-08-13 CN CN201510979350.1A patent/CN105561295B/zh active Active
- 2010-08-13 CN CN201510979490.9A patent/CN105535938B/zh active Active
- 2010-08-13 EP EP16186033.3A patent/EP3117829B1/en active Active
- 2010-08-13 KR KR1020187020803A patent/KR20180085825A/ko not_active Ceased
- 2010-08-13 CN CN201510979291.8A patent/CN105412908B/zh active Active
- 2010-08-13 NZ NZ623113A patent/NZ623113A/en unknown
- 2010-08-13 CN CN202110879546.9A patent/CN113577291A/zh active Pending
- 2010-08-13 KR KR1020127004678A patent/KR101882521B1/ko active Active
- 2010-08-13 CA CA2770822A patent/CA2770822C/en active Active
- 2010-08-13 CN CN201080045618.XA patent/CN102655872B/zh active Active
- 2010-08-13 RU RU2016123808A patent/RU2642302C1/ru active
- 2010-08-13 BR BR122020019169-4A patent/BR122020019169B1/pt active IP Right Grant
- 2010-08-13 NZ NZ598348A patent/NZ598348A/en unknown
- 2010-08-13 MX MX2012001916A patent/MX2012001916A/es active IP Right Grant
-
2012
- 2012-02-12 IL IL218052A patent/IL218052A/en active IP Right Grant
- 2012-02-13 MX MX2019010341A patent/MX2019010341A/es unknown
-
2015
- 2015-12-03 JP JP2015236828A patent/JP2016034981A/ja not_active Withdrawn
-
2017
- 2017-05-01 IL IL252045A patent/IL252045B/en active IP Right Grant
- 2017-05-01 IL IL252046A patent/IL252046B/en active IP Right Grant
- 2017-05-01 IL IL25204417A patent/IL252044B/en active IP Right Grant
-
2018
- 2018-08-17 JP JP2018153528A patent/JP6860533B2/ja active Active
-
2020
- 2020-07-05 IL IL275851A patent/IL275851B/en unknown
- 2020-09-29 JP JP2020163806A patent/JP2020203953A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013501816A5 (https=) | ||
| Parvez et al. | PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment | |
| Hamid et al. | Intratumoral immunotherapy—update 2019 | |
| RU2012109393A (ru) | Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов | |
| Arnold et al. | The impact of radiation on the tumor microenvironment: effect of dose and fractionation schedules | |
| Chuntova et al. | Genetically engineered T-cells for malignant glioma: overcoming the barriers to effective immunotherapy | |
| Koh et al. | Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage | |
| US10525106B2 (en) | Angiopoietin-based interventions for treating cerebral malaria | |
| JP2017533910A5 (https=) | ||
| WO2015024667A8 (en) | Method for increasing expression of rna-encoded proteins | |
| Brunckhorst et al. | Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis | |
| Nowacka et al. | Angiogenesis in glioblastoma—treatment approaches | |
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| Wei et al. | Pioglitazone alleviates cardiac fibrosis and inhibits endothelial to mesenchymal transition induced by pressure overload | |
| JP2017501381A5 (https=) | ||
| JP2017530130A5 (https=) | ||
| JP2020517658A5 (https=) | ||
| JP2021514661A5 (https=) | ||
| Ding et al. | Anti‑neuropilin‑1 monoclonal antibody suppresses the migration and invasion of human gastric cancer cells via Akt dephosphorylation | |
| JP2015514115A5 (https=) | ||
| Nguyen et al. | A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma | |
| Lu et al. | Vascular endothelial growth factor B promotes transendothelial fatty acid transport into skeletal muscle via histone modifications during catch-up growth | |
| Oglesby et al. | Intratumoral and combination therapy in melanoma and other skin cancers | |
| KR20200144576A (ko) | 화학요법-유발 말초신경병증과 관련된 신경병증성 통증의 치료 | |
| JP2014129405A5 (https=) |